Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.

"Guarantor of the article: Jean-Frederic Colombel, MD.: Specific author contributions: J.-F.C., W.J.S., S.G., D.C.W., R.P., B.F., and W.R. collected data; M.K. and B.H. performed statistical analyses; J.-F.C., W.J.S., S.G., D.C.W., R.P., B.F., W.R., A.M.R., A.L., B.D., and R.B.T. contributed to the design of the analyses. All authors contributed to the interpretation of data and critical review and revision of each draft of the manuscript. All authors had access to the data and approved the final version for submission.: Financial support: AbbVie funded the studies and the analyses, provided writing support, and reviewed and approved the publication.: Potential competing interests: J.-F. Colombel reports having served as consultant, advisory board member or speaker for AbbVie, Bristol Meyers Squibb, Ferring, Genentech, Giuliani SPA, Given Imaging, Merck, Millenium Pharmaceuticals, Pfizer, Prometheus Laboratories, Sanofi, Schering Plough Corporation, Takeda, Teva Pharmaceuticals, and UCB Pharma (previously named Celltech Therapeutics). W.J. Sandborn reports having received consulting fees from AbbVie, ActoGeniX NV, AGI Therapeutics, Alba Therapeutics Corporation, Albireo, Alfa Wasserman, Amgen, AM-Pharma BV, Anaphore, Astellas, Athersys, Atlantic Healthcare Limited, Aptalis, BioBalance Corporation, Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Celek Pharmaceuticals, Cellerix SL, Cerimon Pharmaceuticals, ChemoCentryx, CoMentis, Cosmo Technologies, Coronado Biosciences, Cytokine Pharmasciences, Eagle Pharmaceuticals, Eisai Medical Research, Elan Pharmaceuticals, EnGene, Eli Lilly, Enteromedics, Exagen Diagnostics, Ferring Pharmaceuticals, Flexion Therapeutics, Funxional Therapeutics Limited, Genzyme Corporation, Genentech, Gilead Sciences, Given Imaging, GlaxoSmithKline, Human Genome Sciences, Ironwood Pharmaceuticals, Janssen, KaloBios Pharmaceuticals, Lexicon Pharmaceuticals, Lycera Corporation, Meda Pharmaceuticals, Merck Research Laboratories, MerckSerono, Merck, Millennium, Nisshin Kyorin Pharmaceuticals, Novo Nordisk A/S, NPS Pharmaceuticals, Optimer Pharmaceuticals, Orexigen Therapeutics, PDL Biopharma, Pfizer, Procter and Gamble, Prometheus Laboratories, ProtAb Limited, Purgenesis Technologies, Receptos, Relypsa, Salient Pharmaceuticals, Salix Pharmaceuticals, Santarus, Shire Pharmaceuticals, Sigmoid Pharma Limited, Sirtris Pharmaceuticals(a GSK company), S.L.A. Pharma (UK) Limited, Targacept, Teva Pharmaceuticals, Therakos, Tillotts Pharma AG, TxCell SA, UCB Pharma, Viamet Pharmaceuticals, Vascular Biogenics Limited (VBL), and Warner Chilcott UK Limited. He has received lecture fees from AbbVie, Bristol-Myers Squibb, and Janssen. He has received research support from AbbVie, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Millennium, Novartis, Pfizer, Procter and Gamble Pharmaceuticals, Shire Pharmaceuticals, and UCB Pharma. S. Ghosh reports having received consulting and/or lecture fees from AbbVie, Shire, Pfizer, Bristol-Myers Squibb, Janssen, and Merck. He has served on an advisory committee or review panel for AbbVie and Merck. He has received research support from AbbVie. D.C. Wolf reports having received consulting fees from AbbVie, Elan Pharmaceuticals, Genentech, Given Imaging, Janssen, Prometheus Laboratories, Salix Pharmaceuticals, UCB Pharma, and Warner Chilcott. He has received lectures fees from AbbVie, Janssen, Prometheus Laboratories, Santarus, Salix Pharmaceutical, Shire Pharmaceutical, and UCB Pharma. He has received research support from AbbVie, Elan Pharmaceuticals, Given Imaging, GlaxoSmithKline, Genentech, Janssen, Millennium Pharmaceutical, Pfizer, Prometheus Laboratories, Receptos, Shire Pharmaceutical, Tsumura, and UCB Pharma. R. Panaccione reports having received consulting and/or lecture fees from AbbVie, Amgen, AstraZeneca, Axcan Pharma (now Aptalis), Biogen Idec, Bristol-Myers Squibb, Centocor, ChemoCentryx, Eisai Medical Research, Elan Pharmaceuticals, Ferring, Genetech, GlaxoSmithKline, Janssen, Merck Sharp and Dohme, Millennium Pharmaceuticals (now Takeda), Ocera Therapeutics, Otsuka America Pharmaceutical, Pfizer, Shire Pharmaceuticals, Prometheus Laboratories, Schering-Plough, Synta Pharmaceuticals, Teva, UCB Pharma, and Warner Chilcott. B. Feagan reports having received consulting fees from Millennium, Merck, Centocor, Elan/Biogen, Janssen-Ortho, Teva Pharmaceuticals, Bristol-Myers Squibb, Celgene, UCB Pharma, AbbVie, Astra Zeneca, Serono, Genentech, Tillotts Pharma AG, Unity Pharmaceuticals, Albireo Pharma, Given Imaging, Salix Pharmaceuticals, Novonordisk, GSK, Actogenix, Prometheus Therapeutics and Diagnostics, Athersys, Axcan, Gilead, Pfizer, Shire, Wyeth, Zealand Pharma, Zyngenia, GiCare Pharma, and Sigmoid Pharma. He has received lecture fees from AbbVie, UCB, and Janssen. He has received research support from Millennium Pharmaceuticals, Merck, Tillotts Pharma AG, AbbVie, Novartis, Centocor, Elan/Biogen, UCB Pharma, Bristol-Myers Squibb, Genentech, ActoGenix, and Wyeth. W. Reinisch reports having served as a speaker, a consultant, and/or an advisory board member for AbbVie, Aesca, Amgen, Astellas, Astra Zeneca, Biogen IDEC, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Janssen, Danone Austria, Elan, Ferring, Genentech, Grìnenthal, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Robarts Clinical Trial, Schering-Plough, Setpointmedical, Shire, Takeda, Therakos, Tigenix, UCB, Vifor, Yakult, Zyngenia, Austria, and 4SC. A.M. Robinson, A. Lazar, M. Kron, B. Huang, M. Skup, and R.B. Thakkar are employees of AbbVie and may own AbbVie stock and/or options."

"Financial support : AbbVie funded the studies and the analyses, provided writing support, and reviewed and approved the publication."